Hives (Urticaria): Causes, Treatment & When to Seek Emergency Care

## Overview Hives — medically known as **urticaria** (ICD-10: L50) — are raised, itchy welts (wheals) on the skin that range in size from a few millimeters to several centimeters. Individual wheals are typically pale or pink, surrounded by a red flare, and characteristically migrate and resolve within 24 hours, although new lesions may continue to appear. Urticaria is one of the most common dermatologic conditions encountered in both primary care and emergency settings. **Prevalence.** Approximately 15–25 % of the general population will experience at least one episode of urticaria during their lifetime [1]. Acute urticaria (lasting < 6 weeks) accounts for the majority of cases and is especially common in children and young adults. Chronic urticaria — defined as recurrent wheals persisting for 6 weeks or longer — affects roughly 0.5–1 % of the population at any given time and disproportionately affects women aged 20–40 [2]. The condition significantly impairs quality of life; studies report sleep disruption, anxiety, and reduced work productivity comparable to that seen in moderate-to-severe eczema. **Why people search for it.** Hives can appear suddenly, look alarming, and cause intense pruritus (itch). Many individuals search online because they want to understand whether their rash is dangerous, whether it could signal an allergic reaction or anaphylaxis, what over-the-counter remedies are effective, and when to seek professional care. > **Disclaimer:** This article is for educational purposes only and does not replace individualized medical advice. Always consult a qualified healthcare provider for diagnosis and treatment. --- ## Common Causes Urticaria results from the activation of mast cells in the superficial dermis, leading to release of histamine and other vasoactive mediators. This causes localized vasodilation, increased vascular permeability, and sensory nerve stimulation — producing the classic triad of swelling, redness, and itch. Causes are ranked below roughly by frequency in clinical practice. ### 1. Acute Allergic (IgE-Mediated) Urticaria The most recognizable trigger. Exposure to an allergen (food, insect venom, medication, latex) causes cross-linking of IgE on mast-cell surfaces, triggering degranulation. Common culprits include shellfish, tree nuts, peanuts, eggs, penicillins, and NSAIDs. Onset is usually within minutes to 1–2 hours of exposure. ### 2. Infection-Associated Urticaria Viral upper-respiratory infections are the single most common identifiable trigger of acute urticaria in children and a frequent cause in adults [3]. Bacterial infections (e.g., *Helicobacter pylori*, urinary tract infections) and, less commonly, parasitic infections may also provoke hives through immune-complex or direct mast-cell activation. ### 3. Drug-Induced (Non-Allergic) Urticaria Some medications trigger urticaria through non-IgE pharmacologic mechanisms. NSAIDs (ibuprofen, aspirin) inhibit cyclooxygenase-1, shunting arachidonic acid toward leukotriene pathways that activate mast cells. ACE inhibitors can cause angioedema (with or without hives) via bradykinin accumulation. Opioids cause direct, non-immune mast-cell degranulation. ### 4. Physical (Inducible) Urticaria Mechanical or environmental stimuli provoke wheals in susceptible individuals: - **Dermatographism (symptomatic):** Wheals at sites of skin stroking or pressure; the most common physical urticaria, affecting ~2–5 % of the population. - **Cold urticaria:** Wheals on cold-exposed skin; confirmed by ice-cube provocation test. - **Cholinergic urticaria:** Small (2–4 mm) punctate wheals triggered by a rise in core body temperature (exercise, hot bath, emotional stress). - **Delayed pressure urticaria:** Deep swelling 4–6 hours after sustained pressure (waistband, tool handle). - **Solar urticaria:** Wheals within minutes of UV or visible light exposure. ### 5. Chronic Spontaneous Urticaria (CSU) When hives recur for ≥ 6 weeks without an identifiable external trigger, the diagnosis is CSU. Approximately 30–50 % of CSU patients have functional IgG autoantibodies against the high-affinity IgE receptor (FcεRI) or against IgE itself, causing chronic mast-cell activation [4]. CSU is often associated with autoimmune thyroid disease. ### 6. Contact Urticaria Direct skin contact with an urticant (e.g., latex, certain plants, cosmetic preservatives) causes localized wheals. This may be immunologic (IgE-mediated) or non-immunologic (direct histamine release). ### 7. Other / Rare Causes - **Urticarial vasculitis:** Wheals that last > 24 hours in the same location, often painful rather than itchy, and leave bruising; associated with hypocomplementemia and systemic disease. - **Mast-cell disorders (mastocytosis):** Consider when urticaria is accompanied by flushing, syncope, or persistently elevated baseline tryptase. - **Hereditary angioedema (HAE):** Recurrent angioedema *without* hives, caused by C1-inhibitor deficiency — not true urticaria, but frequently misdiagnosed as such. --- ## RED FLAGS The following signs may indicate **anaphylaxis**, **angioedema with airway compromise**, or **serious systemic disease**. Seek **emergency care (call 911 / go to the ER)** if hives are accompanied by: - **Difficulty breathing, wheezing, or stridor** — suggests laryngeal or bronchial involvement - **Swelling of the tongue, lips, or throat** — risk of airway obstruction - **Dizziness, lightheadedness, or fainting** — possible anaphylactic hypotension - **Rapid pulse or a feeling of impending doom** - **Abdominal cramping, vomiting, or diarrhea** occurring with hives after a known allergen exposure - **Hives following an insect sting** in a person with known venom allergy - **Hives with fever, joint pain, and elevated ESR/CRP** — consider serum sickness or urticarial vasculitis - **Individual wheals lasting > 24 hours in the same location**, especially if painful or leaving bruises — warrants biopsy to rule out urticarial vasculitis - **Hives in an infant < 6 months** — unusual and may signal a systemic condition > **If you have been prescribed an epinephrine auto-injector, use it immediately at the first signs of anaphylaxis and then call emergency services.** --- ## Self-Care at Home For mild, uncomplicated hives without red-flag features, the following non-pharmacological measures may provide relief: 1. **Cool compresses.** Apply a clean, cool (not ice-cold) damp cloth to affected areas for 10–15 minutes. Cold causes local vasoconstriction and may reduce histamine release. 2. **Lukewarm baths with colloidal oatmeal.** Colloidal oatmeal (Avena sativa) has demonstrated anti-inflammatory and anti-itch properties in clinical studies and is generally well tolerated [5]. 3. **Loose, breathable clothing.** Tight clothing and friction worsen dermatographism and pressure urticaria. 4. **Avoid known triggers.** If a pattern has been identified (food, medication, temperature), strict avoidance is the most effective prevention. 5. **Stress management.** Psychological stress can exacerbate CSU. Techniques such as mindfulness meditation, cognitive-behavioral therapy, and regular exercise may reduce flare frequency in some patients. 6. **Avoid aggravating factors.** Alcohol, very hot baths, and spicy foods can lower the mast-cell degranulation threshold and worsen symptoms. 7. **Keep a symptom diary.** Recording timing, diet, activities, medications, and stress levels helps identify patterns and assists clinicians in evaluation. 8. **Moisturize.** Maintaining an intact skin barrier with fragrance-free emollients may reduce the irritability of the skin. --- ## OTC Medications That Help Second-generation (non-sedating) H1-antihistamines are the cornerstone of urticaria therapy and are recommended as first-line treatment by all major guidelines [1][2]. | Class | Example (Brand) | Typical Adult Dose | Notes | |---|---|---|---| | **2nd-gen H1-antihistamine** | Cetirizine (Zyrtec) | 10 mg once daily | Fast onset (~1 h); may cause mild drowsiness in some individuals. Available as tablets, liquid, and dissolvable tabs. | | **2nd-gen H1-antihistamine** | Loratadine (Claritin) | 10 mg once daily | Least sedating of the class; hepatically metabolized — use caution in severe liver disease. | | **2nd-gen H1-antihistamine** | Fexofenadine (Allegra) | 180 mg once daily | Truly non-sedating; take with water (fruit juice may reduce absorption). | | **1st-gen H1-antihistamine** | Diphenhydramine (Benadryl) | 25–50 mg every 4–6 h (max 300 mg/day) | Significant sedation; anticholinergic side effects (dry mouth, urinary retention, blurred vision). Avoid in elderly — increased fall risk. Use only for acute breakthrough or nocturnal symptoms. | | **H2-antihistamine (adjunct)** | Famotidine (Pepcid) | 20 mg twice daily | ~15 % of skin histamine receptors are H2; adding famotidine to an H1-blocker may provide modest additive benefit in refractory cases, though evidence is mixed [6]. | | **Topical anti-itch** | Calamine lotion | Apply to affected areas as needed | Provides cooling relief; does not treat the underlying mechanism. | | **Topical anti-itch** | Menthol 1–2 % in aqueous cream | Apply to affected areas as needed | Activates cold receptors (TRPM8), producing a cooling sensation that can temporarily mask itch. | ### Important notes on OTC use: - **First-generation antihistamines** (diphenhydramine, chlorpheniramine, hydroxyzine OTC) cross the blood–brain barrier and cause sedation, impaired driving, and anticholinergic effects. Current international guidelines recommend against their routine use in favor of second-generation agents [1]. - **Do not exceed recommended doses** of any OTC antihistamine without consulting a clinician. - **Topical corticosteroids** are generally **not effective** for urticaria (unlike eczema), because the pathology is deeper in the dermis. - **Contraindications for antihistamines:** Cetirizine and loratadine should be used with caution in severe renal or hepatic impairment, respectively. Diphenhydramine is contraindicated in narrow-angle glaucoma and should be avoided with other CNS depressants or alcohol. --- ## Prescription Options Prescription therapy is generally considered when standard-dose OTC antihistamines fail to control symptoms after 2–4 weeks, or when chronic spontaneous urticaria significantly impairs quality of life. | Class | Example | Typical Adult Dose | Notes / Who Prescribes | |---|---|---|---| | **Up-dosed 2nd-gen H1-antihistamine** | Cetirizine, fexofenadine, or loratadine at 2–4× standard dose | e.g., Cetirizine 20–40 mg/day | International guidelines endorse up-dosing (up to 4× the licensed dose) as the second step before adding other agents [1]. Prescribed by GP, allergist, or dermatologist. | | **H1-antihistamine (Rx-only)** | Hydroxyzine (Atarax/Vistaril) | 25–50 mg at bedtime or TID | First-generation; significant sedation. May be added for nocturnal symptoms. QT prolongation risk at high doses. Prescribed by GP or specialist. | | **Leukotriene receptor antagonist (adjunct)** | Montelukast (Singulair) | 10 mg once daily | May benefit patients with NSAID-sensitive urticaria or those with concurrent asthma. FDA boxed warning for neuropsychiatric events (mood changes, suicidality) — discuss risks [7]. Prescribed by GP, allergist, or dermatologist. | | **Anti-IgE monoclonal antibody** | Omalizumab (Xolair) | 150–300 mg subcutaneously every 4 weeks | FDA-approved for CSU refractory to H1-antihistamines in patients ≥ 12 years. A landmark RCT demonstrated significant reduction in itch and wheal scores vs. placebo [4]. Prescribed and typically administered by allergist or dermatologist. | | **Immunosuppressant** | Cyclosporine A (Neoral) | 3–5 mg/kg/day (short-term) | Reserved for severe, refractory CSU. Effective but carries significant risks: nephrotoxicity, hypertension, immunosuppression. Requires monitoring of renal function and blood pressure. Prescribed by specialist only. | | **Short-course systemic corticosteroid** | Prednisone | 20–40 mg/day for 3–7 days (taper) | May be used for severe acute flares or as a bridge while other therapies take effect. NOT recommended for long-term use due to cumulative side effects (osteoporosis, adrenal suppression, hyperglycemia). Prescribed by GP or specialist. | | **Epinephrine auto-injector** | EpiPen, Auvi-Q | 0.3 mg intramuscular (auto-injector) | Prescribed for patients with a history of anaphylaxis associated with urticaria. Every patient at risk should carry two auto-injectors. Prescribed by any physician. | ### Stepwise approach (per EAACI/GA²LEN/EuroGuiDerm 2022 guideline [1]): 1. Standard-dose second-generation H1-antihistamine 2. Increase dose up to 4-fold 3. Add omalizumab 4. Add cyclosporine A (or alternative immunosuppressant) --- ## Lab Tests Typically Ordered For a single episode of acute urticaria that responds to antihistamines, laboratory testing is generally **not necessary**. Testing is primarily indicated for chronic urticaria (≥ 6 weeks), recurrent episodes, or when an underlying systemic cause is suspected. | Test | Rationale | |---|---| | **Complete blood count (CBC) with differential** | Eosinophilia may suggest allergic or parasitic etiology; basopenia is sometimes observed in active CSU. [See: /tests/complete-blood-count](/tests/complete-blood-count) | | **C-reactive protein (CRP) and/or erythrocyte sedimentation rate (ESR)** | Elevated inflammatory markers may point toward urticarial vasculitis or underlying infection. [See: /tests/crp-test](/tests/crp-test) | | **Thyroid function tests (TSH, free T4) and anti-thyroid antibodies (anti-TPO)** | Autoimmune thyroid disease is associated with CSU in 10–27 % of cases. Treating subclinical hypothyroidism may improve urticaria in some patients. [See: /tests/thyroid-function](/tests/thyroid-function) | | **Total IgE** | Helps guide omalizumab dosing decisions, though omalizumab for CSU is dosed independently of IgE level. May be elevated in allergic urticaria. [See: /tests/ige-total](/tests/ige-total) | | **Specific IgE panels or skin-prick testing** | When a specific allergen trigger is suspected (food, venom, drug). Should be guided by clinical history — broad, untargeted panels are discouraged due to high false-positive rates. | | **Complement levels (C3, C4, CH50)** | Ordered when urticarial vasculitis is suspected (painful wheals lasting > 24 hours, residual purpura). Low C4 may also suggest hereditary angioedema. | | **Tryptase (baseline)** | If mast-cell activation syndrome or mastocytosis is considered; persistently elevated baseline tryptase (> 20 ng/mL) warrants hematology referral. [See: /tests/tryptase](/tests/tryptase) | | **Autologous serum skin test (ASST) or basophil activation test** | Functional assays to detect autoantibodies against FcεRI or IgE in CSU; not widely available but can guide treatment decisions. | | **Skin biopsy** | Indicated when individual wheals last > 24 hours, are painful, or leave bruising — to rule out urticarial vasculitis (leukocytoclastic vasculitis on histology). | | ***H. pylori* testing** | Some guidelines recommend testing in chronic urticaria, as eradication has been associated with improvement in a subset of patients, though evidence remains debated. | --- ## Special Populations ### Children - Acute urticaria is very common in children and is most frequently triggered by viral infections rather than food allergy. - Second-generation antihistamines are the mainstay of treatment. **Dosing must follow age- and weight-based pediatric guidelines** — consult the product labeling or a pediatrician before administering any antihistamine to a child. - Cetirizine oral solution and loratadine syrup are available in pediatric formulations. The FDA has approved cetirizine for children ≥ 6 months and loratadine for children ≥ 2 years. - **Avoid first-generation antihistamines in young children** due to paradoxical excitation, respiratory depression risk, and anticholinergic toxicity. - Omalizumab is FDA-approved for CSU in adolescents ≥ 12 years. ### Pregnancy - Urticaria may flare during pregnancy due to immunologic shifts. - **Loratadine and cetirizine** are generally considered compatible with pregnancy based on available human data and are preferred first-line agents. Both were formerly classified as FDA Pregnancy Category B (now described under the PLLR narrative format) [7]. - **First-generation antihistamines** (diphenhydramine, chlorpheniramine) have a longer safety track record in pregnancy but carry sedation and anticholinergic risks. - **Avoid high-dose systemic corticosteroids** in the first trimester (associated with a small increased risk of oral clefts). - **Omalizumab:** Limited pregnancy data; the EXPECT registry has not identified major safety signals, but use should be reserved for cases where benefits clearly outweigh risks. Consult a maternal-fetal medicine specialist. - **Cyclosporine** is generally avoided in pregnancy due to risks of prematurity and low birth weight. - Montelukast should be used only if clearly needed (insufficient human pregnancy data). ### Elderly - **Avoid first-generation antihistamines** (diphenhydramine, hydroxyzine) in older adults — they are listed on the Beers Criteria as potentially inappropriate medications due to increased risk of confusion, falls, urinary retention, and cognitive impairment. - Second-generation antihistamines are preferred. Cetirizine may still cause some sedation in this population; fexofenadine or loratadine may be better tolerated. - Renal dose adjustments may be necessary for cetirizine (reduce to 5 mg daily if CrCl < 30 mL/min). - Drug interactions are more likely given polypharmacy — review for additive CNS depression and QT-prolonging combinations. ### Athletes - **Exercise-induced urticaria (EIU)** and **exercise-induced anaphylaxis (EIA)** are recognized conditions. In EIA, hives progress to systemic anaphylaxis during exertion; a specific subtype is food-dependent exercise-induced anaphylaxis (FDEIA), where symptoms occur only when exercise follows ingestion of a specific food (commonly wheat or shellfish). - Athletes with EIA should carry an epinephrine auto-injector during training and competition, exercise with a partner, and avoid identified trigger foods for at least 4–6 hours before exercise. - Non-sedating antihistamines taken 1–2 hours before exercise may reduce EIU symptoms, though they do **not** reliably prevent anaphylaxis. - Note that **diphenhydramine is not banned** by the World Anti-Doping Agency (WADA), but its sedating effects impair performance. Second-generation antihistamines are preferred and are not prohibited substances. --- ## When to Escalate Use the following guide to determine the appropriate level of care: ### Call 911 / Go to the Emergency Room immediately if: - Hives occur with **difficulty breathing, throat tightness, tongue swelling, or hoarse voice** - Signs of **anaphylaxis**: hives plus hypotension, tachycardia, dizziness, loss of consciousness - Hives develop **rapidly after a known allergen exposure** (food, medication, insect sting) with any systemic symptoms - The patient has **used an epinephrine auto-injector** — they still require ER evaluation and at least 4 hours of observation for biphasic reactions ### See a doctor the same day / Urgent Care if: - Widespread hives covering a large body surface area that are not responding to OTC antihistamines - Hives accompanied by **fever, joint pain, or general malaise** (consider serum sickness, vasculitis, or infection) - **Facial or periorbital angioedema** without airway compromise - Hives following initiation of a **new medication** — the drug may need to be discontinued under medical supervision - Significant distress or inability to sleep or function ### Schedule a GP or specialist appointment within 1–2 weeks if: - Hives have been recurring for **more than 2 weeks** without a clear trigger - OTC antihistamines provide only **partial relief** - You suspect a **food or drug allergy** and need formal allergy testing - You have **chronic hives (≥ 6 weeks)** — referral to an allergist or dermatologist is generally appropriate for further evaluation and consideration of step-up therapy ### Specialist referral (allergist, dermatologist, or immunologist) is indicated for: - CSU uncontrolled on up-dosed antihistamines - Suspected inducible urticaria requiring provocation testing - Consideration of omalizumab or immunosuppressive therapy - Suspected urticarial vasculitis, mast-cell disorder, or hereditary angioedema --- ## References [1] Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. *Allergy*. 2022;77(3):734-766. PMID:34536239. [2] Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. *J Allergy Clin Immunol*. 2014;133(5):1270-1277. PMID:24766875. [3] Sackesen C, Sekerel BE, Orhan F, et al. The etiology of different forms of urticaria in childhood. *Pediatr Dermatol*. 2004;21(2):102-108. PMID:15078346. [4] Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. *N Engl J Med*. 2013;368(10):924-935. PMID:23432142. [5] Reynertson KA, Garay M, Nebus J, et al. Anti-inflammatory activities of colloidal oatmeal (Avena sativa) contribute to the effectiveness of oats in treatment of itch associated with dry, irritated skin. *J Drugs Dermatol*. 2015;14(1):43-48. PMID:25607907. [6] Fedorowicz Z, van Zuuren EJ, Hu N. Histamine H2-receptor antagonists for urticaria. *Cochrane Database Syst Rev*. 2012;(3):CD008596. PMID:22419335. [7] U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA requires Boxed Warning about serious mental health side effects for the asthma and allergy drug montelukast (Singulair). March 2020. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug. [8] NICE Clinical Knowledge Summaries. Urticaria. Last revised 2023. Available at: https://cks.nice.org.uk/topics/urticaria/. [9] By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. *J Am Geriatr Soc*. 2023;71(7):2052-2081. PMID:37139824. --- *Last reviewed: April 2026. This article is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider for diagnosis and treatment decisions.*